mHSPC
mHSPC
Metastatic hormone-sensitive prostate cancer
Advertisement
Ana Kiess, MD, PhDmHSPC | November 21, 2024
Ana Kiess, MD, PhD, of Johns Hopkins Medicine, reviews the phase II RAVENS trial on radium-223 with SABR versus SABR alone.
View More
Emily MenendezmHSPC | November 19, 2024
The phase II UpFrontPSMA study evaluated the use of [177Lu]Lu-PSMA-617 administered before docetaxel.
Marc Greenstein, DOmCSPC | October 31, 2024
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
Andrew Laccetti, MD, MSnmHSPC | September 25, 2024
At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial.
Andrew Laccetti, MD, MSmHSPC | September 25, 2024
Experts discuss mHSPC discuss risk stratification, developed novel approaches for treatment, and treatment sequencing.
Emily MenendezmHSPC | February 28, 2024
Phase III mHSPC trials can take up to a decade to complete when OS is used as the primary endpoint.
Emily MenendezmCSPC | October 12, 2023
The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.
Emily MenendezmCSPC | October 12, 2023
Patients with a suboptimal PSA response who are administered intensified ADT often experience worse survival outcomes.
Emily MenendezProstate Cancer | October 12, 2023
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Emily MenendezProstate Cancer | October 12, 2023
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Emily MenendezASCO 2023 | October 12, 2023
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
Emily MenendezmCSPC | October 12, 2023
Researchers studied several trials including LATITUDE and STAMPEDE to find similar characteristics among ARAT treatments.
Emily MenendezAUA 2023 | October 12, 2023
The STAMPEDE trial examined the addition of zoledronic acid, docetaxel, or both to ADT for the treatment of mHSPC.
Leah LawrenceProstate Cancer | October 12, 2023
Several physicians highlight the newest data on radiation for metastatic prostate cancer and its role moving forward.
Emily MenendezmCSPC | October 12, 2023
New research has reported updates on the primary OS analysis of the ENZAMET trial to define the benefit of enzalutamide.
Emily MenendezExpert Interviews | October 12, 2023
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
David Ambinder, MDmCSPC | October 12, 2023
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
Zachary BessetteASCO GU Symposium 2023 | October 12, 2023
An analysis highlighted real-world treatment of patients with mHSPC in the community who received at least 1 line of therapy.
Tanya Dorff, MDmCSPC | October 12, 2023
Tanya Dorff, MD, shares the barriers to utilizing PARP inhibitors plus AR-targeted agents in early prostate cancer settings.
Matthew Deek, MDmCSPC | October 12, 2023
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
Advertisement
Advertisement
Advertisement